血管ステント市場：製品タイプ、コーティング、エンドユーザー、地域別、2024年～2031年

血管ステント市場の評価、2024年～2031年

心血管疾患の有病率の増加は、人口の高齢化、座りがちなライフスタイル、食生活の乱れに関連しています。薬剤溶出性ステントや生体吸収性ステントなどの新しいステント技術によって治療成績が向上し、2024年には93億8,000万米ドル、2031年には143億6,000万米ドルに達する勢いです。

さらに、低侵襲手術の増加とヘルスケアインフラの改善、革新的な医療技術へのアクセスが、特に新興地域で市場拡大を後押ししています。好意的な償還政策や血管の健康に対する意識の高まりも市場成長の原動力となっており、2024年から2031年にかけてCAGR約5.47％で市場が成長すると予想されます。

血管ステント市場定義/概要

血管ステントは、狭窄または閉塞した動脈を開口して支え、心血管系疾患の治療において正常な血流を確保するメッシュ状の小型医療機器です。血管ステントは一般に、冠動脈疾患、末梢動脈疾患、動脈瘤などの疾患を治療するための血管形成術に使用され、動脈を開いた状態に保ち、将来の閉塞リスクを低下させます。血管ステントの将来は、患者の予後を改善し、問題を軽減し、長期的な利点をもたらす生体吸収性ステント、薬剤溶出性ステント、改良型コーティングの開発にあります。低侵襲手技の革新や新興国での受け入れ拡大が、この分野の今後の成長に拍車をかけると思われます。

心血管疾患の増加は血管ステント市場を促進するか？

心血管疾患（CVD）の世界の負担は増加の一途をたどっており、血管ステントのような効果的な代替治療へのニーズが高まっています。世界保健機関（WHO）によると、CVDは依然として世界最大の死因であり、死亡者全体の31%を占めていると推定されています。米国疾病予防管理センターは、毎年約65万5,000人のアメリカ人が心臓病が原因で死亡していることを明らかにしました。

2024年4月、米国疾病予防管理センター（CDC）は、公衆衛生プログラムの中で心臓血管の健康を優先し、研究により多くの資金を割き、血管ステントなどの革新的治療へのアクセスを改善しました。このような努力に加え、患者層の拡大や技術の向上が市場を前進させ、ステント治療に対する世界の需要の高まりを満たしています。

ステント血栓症合併リスクの増加は血管ステント市場の成長を阻害するか？

ステント血栓症のリスク増大は、血管ステント市場の成長を阻害する可能性のある重大な課題です。ステント血栓症は、ステント上に血栓が形成される疾患で、心臓発作や死亡さえも含む大きな問題を引き起こす可能性があります。この危険性はヘルスケア従事者や患者に懸念をもたらし、特にリスクの高いグループでのステント使用を減少させる可能性があります。その結果、ヘルスケアプロバイダーは他の治療法を求めたり、リスクを低減するために術後の薬剤アドヒアランスを重視したりするようになり、市場の成長が鈍化する可能性があります。

さらに、こうした安全性への懸念の反動で規制状況が強化され、ステント技術の試験や承認プロセスがより厳格化される可能性もあります。メーカーは、血栓症のリスクを最小限に抑えるより高度なステントを開発しなければならないという新たなプレッシャーに直面する可能性があり、その結果、研究開発費が増加し、新製品のイントロダクションが遅れることになります。全体として、ステントが心血管系治療において重要であることに変わりはないが、血栓症の問題に対する知識や危険性の増大により、ステント設計の革新がこれらの懸念に効果的に対処しない限り、市場の成長は制限される可能性があります。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 血管ステント市場：製品タイプ別

• 冠動脈ステント
• 末梢ステント
• 頸動脈ステント
• 大動脈ステント
• 生体吸収性ステント
• 薬剤溶出ステント（DES）

第5章 血管ステント市場：コーティング別

• 薬剤コーティングステント
• ベアメタルステント
• 生分解性コーティングステント

第6章 血管ステント市場：エンドユーザー別

• 病院
• 外来手術センター（ASC）
• 心臓カテーテル検査室
• クリニックおよび専門医センター

第7章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• Medtronic plc（Ireland）
• Abbott Laboratories（US）
• Boston Scientific Corporation（US）
• BIOTRONIK SE & Co. KG（Germany）
• B. Braun Melsungen AG（Germany）
• Terumo Corporation（Japan）
• Cook Medical（US）
• Cordis Corporation（US）
• MicroPort Scientific Corporation（China）

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

Vascular Stents Market Valuation - 2024-2031

The increasing prevalence of cardiovascular disease is related to aging populations, sedentary lifestyles, and bad diets. New stent technologies, including as drug-eluting and bioresorbable stents, are improving treatment outcomes is fuelling the USD 9.38 Billion in 2024 and reachingUSD 14.36 Billion by 2031.

Furthermore, the increased number of minimally invasive operations, combined with improved healthcare infrastructure and access to innovative medical technologies, especially in emerging regions, is propelling market expansion. Favorable reimbursement policies and increased awareness of vascular health are also driving market growth is fueling market expected to grow at aCAGR of about 5.47% from 2024 to 2031.

Vascular Stents Market: Definition/ Overview

Vascular stents are small, mesh-like medical devices that open and support restricted or obstructed blood arteries, ensuring normal blood flow in the treatment of cardiovascular disease. They are generally utilized in angioplasty operations to treat disorders such as coronary artery disease, peripheral artery disease, and aneurysms by keeping arteries open and lowering the risk of future blockage. The future of vascular stents is in the development of bioresorbable stents, drug-eluting stents, and improved coatings that improve patient outcomes, reduce problems, and provide long-term advantages. Innovations in minimally invasive procedures, as well as increased acceptance in emerging economies, are likely to fuel future growth in this sector.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will Rising Prevalence of Cardiovascular Diseases Propel the Vascular Stents Market?

The global burden of cardiovascular diseases (CVDs) continues to rise, increasing need for effective treatment alternatives such as vascular stents. According to the World Health Organization, CVDs are still the largest cause of death globally, accounting for an estimated 31% of all fatalities. The Centers for Disease Control and Prevention revealed that approximately 655,000 Americans die each year as a result of heart disease.

In April 2024, the US Centers for Disease Control and Prevention (CDC) prioritized cardiovascular health in its public health programs, devoting greater funds to research and improving access to innovative treatments such as vascular stents. These efforts, together with an expanding patient pool and technological improvements, are propelling the market forward and fulfilling rising global demand for stenting treatments.

Will Rising Risk of Stent Thrombosis Complications Hinder the Growth of the Vascular Stents Market?

The increasing risk of stent thrombosis problems is a significant challenge that may impede the growth of the vascular stents market. Stent thrombosis, a disorder in which blood clots form on the stent, can result in major problems, including heart attacks and even death. This danger raises concerns among healthcare practitioners and patients, potentially decreasing stent use, particularly in high-risk groups. As a result, healthcare providers may seek other therapies or place a higher emphasis on post-operative drug adherence to reduce risk, thereby slowing market growth.

Additionally, in reaction to these safety concerns, the regulatory landscape may tighten, resulting in more stringent testing and approval processes for stent technology. Manufacturers may face additional pressure to create more advanced stents that minimize the risk of thrombosis, thereby increasing R&D expenditures and delaying new product introductions. Overall, while stents remain important in cardiovascular treatment, increased knowledge and danger of thrombosis problems may limit market growth unless innovations in stent design effectively address these concerns.

Category-Wise Acumens

Will Increasing Usage of Coronary Stents Propel the Vascular Stents Market?

The increasing use of coronary stents is predicted to greatly boost the vascular stents market. Coronary stents are critical in treating coronary artery disease, which is still a significant cause of death worldwide. The rising prevalence of heart-related illnesses, combined with the expanding use of minimally invasive procedures that use these stents to restore blood flow in clogged arteries, is driving up demand for coronary stents. Furthermore, in April 2024, the European Union increased financing for cardiovascular research, with an emphasis on improving therapeutic technology such as coronary stents. These advancements are driving innovation and fueling market expansion, especially as more patients need stenting treatments to treat cardiovascular problems.

The fastest-growing section is bioresorbable stents, which have the advantage of dissolving over time, lowering long-term problems such restenosis and thrombosis. Bioresorbable stents are rapidly gaining popularity in both developed and emerging economies, owing to continued advances in material science and an increasing preference for least invasive, temporary solutions.

Will Rising Demand for Drug-Coated Stents Fuel the Vascular Stents Market?

The increasing demand for drug-coated stents is projected to drive the vascular stents market. Drug-coated stents, also known as drug-eluting stents, are extremely efficient at reducing restenosis (re-narrowing of arteries) and have become the preferred treatment option for coronary artery disorders. This rising demand is being driven by the superior clinical outcomes that these stents give over bare-metal alternatives, making them indispensable in minimally invasive operations. In July 2024, the FDA approved Abbott's new, enhanced drug-coated stents, which aim to improve long-term results for patients with complicated cardiovascular problems. Meanwhile, in March 2024, the European Medicines Agency issued new rules to speed the clearance procedure for emerging stent technologies, including drug-coated stents, which are expected to boost their global acceptance these developments emphasize the expanding role of drug-coated stents in defining the future of vascular therapy.

Biodegradable coated stents are the fastest-growing class, as they combine the advantages of drug-eluting stents with coatings that disintegrate over time. These stents lessen long-term difficulties and the need for permanent implants, making them more appealing as biodegradable materials develop.

Country/Region-wise

Will Rising Advanced Healthcare Infrastructure in North America Drive the Vascular Stents Market?

The vascular stents market in North America is expected to increase significantly, owing to the region's rapidly improving healthcare infrastructure. As hospitals and medical centers invest in cutting-edge equipment and technology, the use of minimally invasive procedures, such as vascular stenting, is increasing. This tendency is aided by an aging population and rising prevalence of cardiovascular disorders. According to Verified Market Research, the vascular stents market is predicted to reach USD 9.38 Billion by 2023, rising at a 5.47% CAGR from 2023-2031. The market's growth is also aided by ongoing R&D activities, which result in the launched of more advanced and effective stent technologies.

In August 2024, the United States government provided more funds to expand cardiovascular care infrastructure as part of its healthcare reform projects, with an emphasis on improving access to modern medical treatments such as stenting. In May 2024, Boston Scientific announced the expansion of its vascular stents product line in the United States, highlighting the growing demand for advanced stent technologies, such as drug-eluting and bioresorbable stents, in response to the rising prevalence of cardiovascular disease. These improvements are projected to boost the vascular stents market in North America.

Will Rising Demand for Minimally Invasive Procedures in Asia Pacific Propel the Vascular Stents Market?

The Asia Pacific area is seeing an increase in demand for minimally invasive procedures, which is projected to enhance the vascular stents market. This trend is being driven by reasons such as rising cardiovascular disease prevalence, an aging population, and rising healthcare spending in nations such as China, India, and Japan. The demand for minimally invasive procedures over standard open surgeries is growing due to advantages such as faster recovery times, shorter hospital stays, and lower risk of problems. In January 2024, the Indian Ministry of Health and Family Welfare announced a new plan to increase access to sophisticated cardiac care, which includes funding for vascular stent treatments in public hospitals. This approach is intended to expand the use of stents among low-income individuals.

In April 2024, Medtronic announced plans to increase production of vascular stents in China, citing the growing demand for minimally invasive procedures. These investments and government support are expected to drive the adoption of vascular stents, making Asia Pacific one of the fastest-growing regions in this market.

Competitive Landscape

The competitive landscape of the vascular stents market is shaped by intense competition driven by innovation, technological advancements, and the growing demand for minimally invasive procedures. Smaller companies and regional players are increasingly entering the market, offering cost-effective alternatives and focusing on niche areas like bioresorbable stents or drug-eluting stents. In addition, strategic collaborations, mergers, and acquisitions are common as companies seek to enhance their product portfolios and expand their geographic reach. Regulatory approvals and compliance with healthcare standards also play a critical role, creating competitive advantages for companies that can navigate these processes effectively.

Some of the prominent players operating in the vascular stents market include:

Medtronic plc

Abbott Laboratories

Boston Scientific Corporation

Cook Medical, Inc.

Terumo Corporation

Cardinal Health, Inc.

Braun Melsungen AG

R. Bard, Inc.

MicroPort Scientific Corporation

Endologix, Inc.

Latest Developments

In April 2024, the business debuted a new drug-coated peripheral stent in the Asia Pacific region, with the goal of enhancing treatment outcomes for patients with peripheral artery disease, particularly in diabetic populations.

In March 2024, Terumo launched its next-generation bioresorbable stent in Japan, which dissolves over time to reduce long-term issues including thrombosis and promote natural channel repair.

In February 2024, BIOTRONIK increased their offering with the Orsiro Mission, a drug-eluting stent aimed to improve performance in treating coronary artery blockages. The device has acquired CE clearance and is slated to spread into European markets.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Vascular Stents Market, By Type of Product

• Coronary Stents
• Peripheral Stents
• Carotid Stents
• Aortic Stents
• Bioresorbable stents
• Drug-Eluting Stents (DES)

5. Vascular Stents Market, By Coating

• Drug-Coated Stents
• Bare-Metal Stents
• Biodegradable Coated Stents

6. Vascular Stents Market, By End User

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Cardiac Catheterization Laboratories
• Clinics and specialist Centers

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Medtronic plc (Ireland)
• Abbott Laboratories (US)
• Boston Scientific Corporation (US)
• BIOTRONIK SE & Co. KG (Germany)
• B. Braun Melsungen AG (Germany)
• Terumo Corporation (Japan)
• Cook Medical (US)
• Cordis Corporation (US)
• MicroPort Scientific Corporation (China)

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References